Skip to content
Study details
Enrolling now

Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines

Northwell Health
NCT IDNCT07061847ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

40

Study length

about 2.3 years

Ages

18–75

Locations

1 site in NY

About this study

This trial is testing a new treatment to improve chronic migraine symptoms. The treatment involves an infusion of lidocaine into blood vessels in the skull to numb pain receptors, potentially reducing migraine intensity, frequency, and duration.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Lidocaine (drug)
  • 2.Undergo Lidocaine Procedure
PhasePhase 2
DrugLidocaine (drug)
Routetopical

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low11%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

lidocaine, local anesthetic (Blocks sodium channels to numb tissue locally)

Drug routes

topical (Topical Cream)

Endpoints

Secondary: Adverse events at 24 hours and 3 months post-procedure., Mean change from baseline in the Global Assessment of Migraine Severity (GAMS) at 3 months, Sustained freedom from headache pain >48hrs.

Body systems

Neurology